GSK3B and early-onset autosomal dominant Alzheimer disease: Dysfunction of GSK3β is involved in the pathogenesis of several psychoneuroses; therefore, GSK3β has been considered a therapeutic target for Alzheimer’s disease and bipolar disorder (Bhat et al., 2018; Ochoa, 2022).